tetano
Editor, Senior Moderator
Eur Respir Rev
. 2020 Oct 5;29(157):200287.
doi: 10.1183/16000617.0287-2020. Print 2020 Sep 30.
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)
Chunxue Bai[SUP] 1 2 [/SUP], Sanjay H Chotirmall[SUP] 3 [/SUP], Jordi Rello[SUP] 4 5 6 [/SUP], George A Alba[SUP] 7 [/SUP], Leo C Ginns[SUP] 7 [/SUP], Jerry A Krishnan[SUP] 8 [/SUP], Robert Rogers[SUP] 7 [/SUP], Elisabeth Bendstrup[SUP] 9 [/SUP], Pierre-Regis Burgel[SUP] 10 [/SUP], James D Chalmers[SUP] 11 [/SUP], Abigail Chua[SUP] 12 [/SUP], Kristina A Crothers[SUP] 13 [/SUP], Abhijit Duggal[SUP] 14 [/SUP], Yeon Wook Kim[SUP] 15 [/SUP], John G Laffey[SUP] 16 [/SUP], Carlos M Luna[SUP] 17 [/SUP], Michael S Niederman[SUP] 18 [/SUP], Ganesh Raghu[SUP] 19 [/SUP], Julio A Ramirez[SUP] 20 [/SUP], Jordi Riera[SUP] 4 5 21 22 [/SUP], Oriol Roca[SUP] 4 5 21 22 [/SUP], Maximiliano Tamae-Kakazu[SUP] 23 [/SUP], Antoni Torres[SUP] 5 24 [/SUP], Richard R Watkins[SUP] 25 26 [/SUP], Miriam Barrecheguren[SUP] 27 28 [/SUP], Mirko Belliato[SUP] 29 [/SUP], Hassan A Chami[SUP] 30 [/SUP], Rongchang Chen[SUP] 31 [/SUP], Gustavo A Cortes-Puentes[SUP] 32 [/SUP], Charles Delacruz[SUP] 33 [/SUP], Margaret M Hayes[SUP] 34 [/SUP], Leo M A Heunks[SUP] 35 [/SUP], Steven R Holets[SUP] 32 [/SUP], Catherine L Hough[SUP] 36 [/SUP], Sugeet Jagpal[SUP] 37 [/SUP], Kyeongman Jeon[SUP] 38 [/SUP], Takeshi Johkoh[SUP] 39 [/SUP], May M Lee[SUP] 40 [/SUP], Janice Liebler[SUP] 40 [/SUP], Gerry N McElvaney[SUP] 41 [/SUP], Ari Moskowitz[SUP] 34 [/SUP], Richard A Oeckler[SUP] 32 [/SUP], I?igo Ojanguren[SUP] 27 28 [/SUP], Anthony O'Regan[SUP] 42 [/SUP], Mathias W Pletz[SUP] 43 [/SUP], Chin Kook Rhee[SUP] 44 [/SUP], Marcus J Schultz[SUP] 35 [/SUP], Enrico Storti[SUP] 45 [/SUP], Charlie Strange[SUP] 46 [/SUP], Carey C Thomson[SUP] 47 [/SUP], Francesca J Torriani[SUP] 48 [/SUP], Xun Wang[SUP] 49 [/SUP], Wim Wuyts[SUP] 50 [/SUP], Tao Xu[SUP] 51 [/SUP], Dawei Yang[SUP] 1 2 [/SUP], Ziqiang Zhang[SUP] 52 [/SUP], Kevin C Wilson[SUP] 53 [/SUP]
Affiliations
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research.
Methods: An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion.
Results: The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder.
Conclusions: The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities.
. 2020 Oct 5;29(157):200287.
doi: 10.1183/16000617.0287-2020. Print 2020 Sep 30.
Updated guidance on the management of COVID-19: from an American Thoracic Society/European Respiratory Society coordinated International Task Force (29 July 2020)
Chunxue Bai[SUP] 1 2 [/SUP], Sanjay H Chotirmall[SUP] 3 [/SUP], Jordi Rello[SUP] 4 5 6 [/SUP], George A Alba[SUP] 7 [/SUP], Leo C Ginns[SUP] 7 [/SUP], Jerry A Krishnan[SUP] 8 [/SUP], Robert Rogers[SUP] 7 [/SUP], Elisabeth Bendstrup[SUP] 9 [/SUP], Pierre-Regis Burgel[SUP] 10 [/SUP], James D Chalmers[SUP] 11 [/SUP], Abigail Chua[SUP] 12 [/SUP], Kristina A Crothers[SUP] 13 [/SUP], Abhijit Duggal[SUP] 14 [/SUP], Yeon Wook Kim[SUP] 15 [/SUP], John G Laffey[SUP] 16 [/SUP], Carlos M Luna[SUP] 17 [/SUP], Michael S Niederman[SUP] 18 [/SUP], Ganesh Raghu[SUP] 19 [/SUP], Julio A Ramirez[SUP] 20 [/SUP], Jordi Riera[SUP] 4 5 21 22 [/SUP], Oriol Roca[SUP] 4 5 21 22 [/SUP], Maximiliano Tamae-Kakazu[SUP] 23 [/SUP], Antoni Torres[SUP] 5 24 [/SUP], Richard R Watkins[SUP] 25 26 [/SUP], Miriam Barrecheguren[SUP] 27 28 [/SUP], Mirko Belliato[SUP] 29 [/SUP], Hassan A Chami[SUP] 30 [/SUP], Rongchang Chen[SUP] 31 [/SUP], Gustavo A Cortes-Puentes[SUP] 32 [/SUP], Charles Delacruz[SUP] 33 [/SUP], Margaret M Hayes[SUP] 34 [/SUP], Leo M A Heunks[SUP] 35 [/SUP], Steven R Holets[SUP] 32 [/SUP], Catherine L Hough[SUP] 36 [/SUP], Sugeet Jagpal[SUP] 37 [/SUP], Kyeongman Jeon[SUP] 38 [/SUP], Takeshi Johkoh[SUP] 39 [/SUP], May M Lee[SUP] 40 [/SUP], Janice Liebler[SUP] 40 [/SUP], Gerry N McElvaney[SUP] 41 [/SUP], Ari Moskowitz[SUP] 34 [/SUP], Richard A Oeckler[SUP] 32 [/SUP], I?igo Ojanguren[SUP] 27 28 [/SUP], Anthony O'Regan[SUP] 42 [/SUP], Mathias W Pletz[SUP] 43 [/SUP], Chin Kook Rhee[SUP] 44 [/SUP], Marcus J Schultz[SUP] 35 [/SUP], Enrico Storti[SUP] 45 [/SUP], Charlie Strange[SUP] 46 [/SUP], Carey C Thomson[SUP] 47 [/SUP], Francesca J Torriani[SUP] 48 [/SUP], Xun Wang[SUP] 49 [/SUP], Wim Wuyts[SUP] 50 [/SUP], Tao Xu[SUP] 51 [/SUP], Dawei Yang[SUP] 1 2 [/SUP], Ziqiang Zhang[SUP] 52 [/SUP], Kevin C Wilson[SUP] 53 [/SUP]
Affiliations
- PMID: 33020069
- DOI: 10.1183/16000617.0287-2020
Abstract
Background: Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome-coronavirus-2. Consensus suggestions can standardise care, thereby improving outcomes and facilitating future research.
Methods: An International Task Force was composed and agreement regarding courses of action was measured using the Convergence of Opinion on Recommendations and Evidence (CORE) process. 70% agreement was necessary to make a consensus suggestion.
Results: The Task Force made consensus suggestions to treat patients with acute COVID-19 pneumonia with remdesivir and dexamethasone but suggested against hydroxychloroquine except in the context of a clinical trial; these are revisions of prior suggestions resulting from the interim publication of several randomised trials. It also suggested that COVID-19 patients with a venous thromboembolic event be treated with therapeutic anticoagulant therapy for 3 months. The Task Force was unable to reach sufficient agreement to yield consensus suggestions for the post-hospital care of COVID-19 survivors. The Task Force fell one vote shy of suggesting routine screening for depression, anxiety and post-traumatic stress disorder.
Conclusions: The Task Force addressed questions related to pharmacotherapy in patients with COVID-19 and the post-hospital care of survivors, yielding several consensus suggestions. Management options for which there is insufficient agreement to formulate a suggestion represent research priorities.